Use of advanced cardiovascular imaging in rheumatic immune-mediated inflammatory diseases Authors: Leher Gumber, Mohammed Askari Meghji, Vishal Kakkar, Karthikeyan Sivasankaran, Zahra M Iftikhar, Najla Elndari, Charlotte Talbot, Jason M Tarkin, Sven Plein, Marc R Dweck, Taryn Youngstein, Ziad Mallat, Lesley-Anne Bissell, Jonathan Heaney, John Reynolds, Maya H Buch Published: 2026 ABSTRACT AbstractObjectivesTo evaluate the real-world use of advanced cardiovascular imaging in less common and rare rheumatic immune-mediated inflammatory diseases (IMIDs) and identify variation in practice to inform future studies and clinical guidelines.MethodsA retrospective, multicentre quality improvement project was conducted across four major hospitals in the UK. Adults with SLE, SSc, idiopathic inflammatory myopathy, vasculitis or SS who underwent cardiovascular magnetic resonance (CMR), CT coronary angiography (CTCA) or PET between January 2023 and December 2024 were included. Demographics, IMID characteristics, cardiovascular risk factors, imaging indications, findings and management were extracted using a standardized proforma and analysed.ResultsA total of 294 imaging studies were performed in 261 patients (72.4% female, 65.9% aged 40–74 years) comprising 137 (46.6%) CMR, 40 (13.6%) CTCA and 117 (39.8%) PET scans. Indications varied by modality and centre. Cardiovascular abnormalities were reported in 175/294 (59.5%), most commonly in vasculitis (53.7%). Notably, 54/63 (85.7%) of abnormal PET and 61/89 (68.5%) of abnormal CMR scans were in asymptomatic patients. Imaging findings prompted cardiology referral/ongoing follow-up in 59.5% and changes to IMID treatment in 31.3%, but only 23.1% were discussed in a formal multidisciplinary team (MDT).ConclusionAdvanced cardiovascular imaging frequently identifies cardiovascular involvement in rheumatic IMIDs, including in asymptomatic patients. Treatment adjustments occurred in a third of patients, although largely undertaken outside established MDT processes. These findings emphasize the need for better understanding of imaging-based findings and for cardio-rheumatology MDTs to support integrated decision-making to improve patient outcomes.Keywords: immune-mediated inflammatory diseases, cardiovascular disease, imaging Advanced imaging frequently detects cardiovascular involvement in rheumatic diseases, often before symptoms develop. Advanced imaging frequently detects cardiovascular involvement in rheumatic diseases, often before symptoms develop. Imaging indications for rheumatic diseases vary between centres, reflecting differences in expertise and patient populations. Imaging indications for rheumatic diseases vary between centres, reflecting differences in expertise and patient populations. Harmonised imaging protocols and cardio-rheumatology MDTs may improve care for people with rheumatic diseases. Harmonised imaging protocols and cardio-rheumatology MDTs may improve care for people with rheumatic diseases. Introduction People with rheumatic immune-mediated inflammatory diseases (IMIDs) have increased cardiovascular morbidity and mortality relative to the general population [1]. Cardiovascular involvement is wide ranging, not explained fully by traditional risk factors [2] and varies by IMID [3]. Most studies have focused on atherosclerotic cardiovascular disease (ASCVD) in inflammatory arthritis and SLE [1, 4]. However, less common and rare IMIDs including SSc and idiopathic inflammatory myopathies (IIM) are also associated with ASCVD and carry a substantial burden of inflammatory myopericardial involvement, characterized by myopericarditis, microvascular pathology and myocardial fibrosis [3, 5]. Cardiovascular involvement may remain asymptomatic and when overt, signifies poor prognosis, highlighting the need for risk stratification and early detection. Advanced cardiovascular imaging is useful for detection of cardiovascular abnormalities in rheumatic IMIDs. CT coronary angiography (CTCA) demonstrates a high prevalence of coronary atherosclerotic plaque even in patients classified as borderline risk by traditional clinical risk scores [6–8]. Fluoride-18 [18F] fluorodeoxyglucose (FDG) PET is established in the management of large vessel vasculitis (LVV), and with rubidium, is the non-invasive reference standard for coronary microvascular dysfunction [9]. Cardiac magnetic resonance (CMR) provides multiparametric evaluation of myocardial tissue composition, focal fibrosis and ventricular function, morphology and tissue characteristics and is increasingly utilized for inflammatory heart disease in IMIDs [10–12]. Native T1 and extracellular volume reflect diffuse interstitial expansion due to inflammation and fibrosis, whereas T2 mapping identifies myocardial oedema indicating active myocardial inflammation. Importantly, these abnormalities may be detected in the absence of late gadolinium enhancement (LGE) and in the absence of clinical symptoms [10, 13]. The 2021 European Society of Cardiology (ESC) guidelines recommend incorporating advanced imaging alongside traditional cardiovascular risk factor assessment in IMIDs [14] and the recently updated ESC guidelines on the management of myocarditis and pericarditis now consider positive CMR findings diagnostic for myocarditis. An initial survey within the rheumatology community highlighted significant variation in practice and confidence in managing cardio-rheumatology cases [15]. Building on this, we evaluated real-world use of advanced cardiovascular imaging in less common and rare rheumatic IMIDs, and identified variation in clinical practice across four UK major centres. The study was supported by the UK CARDIO-IMID Partnership with the aim to inform and prioritize future national health research on cardiovascular involvement in this high-risk population. Methods This was a retrospective, multicentre evaluation conducted in four major National Health Service (NHS) hospitals in the UK—Manchester University NHS Foundation Trust, Leeds Teaching Hospitals NHS Trust, Newcastle Hospitals NHS Foundation Trust, and Sandwell and West Birmingham NHS Trust as part of audit and/or quality improvement project (QIP). Patients aged ≥18 years with confirmed SLE, IIM, SSc, ANCA-associated vasculitis (AAV), LVV, other vasculitis or SS, who underwent standard of care cross-sectional cardiovascular imaging (CMR, CTCA or PET) between 1 January 2023 and 31 December 2024, were included. Research scans and incomplete reports were excluded. Data were extracted using a standardized proforma capturing demographics, IMID characteristics, DMARDs, cardiovascular risk factors, imaging indications and findings, and details of subsequent management. Imaging indications were categorized as cardiac symptoms (e.g. chest pain, palpitations, breathlessness), non-cardiac symptoms (e.g. fever, other symptoms relating to underlying IMID), raised biomarkers [troponin or pro-B-type natriuretic peptide (proBNP) above the normal reference range of the assay for the trust], IMID evaluation (primary diagnosis or routine surveillance), follow-up of prior abnormal imaging, raised inflammatory markers (ESR and/or CRP) or abnormal echocardiography. Imaging findings were recorded using predefined categories of interest. ‘Abnormal imaging’ was defined as any cardiac abnormality documented within the descriptive sections of imaging reports. For CMR, this encompassed abnormalities in left ventricular ejection fraction (LVEF), chamber dimensions, wall motion, LGE, myocardial or pericardial involvement, valvular structure or function, and great vessel assessment. For PET, categories were myocardial and pericardial uptake, and features of vasculitis (e.g. vessel wall involvement, thickening, aneurysm) or atherosclerosis. For CTCA, categories were number of vessels involved, stenosis severity and coronary artery calcium (CAC) score (Agatson classification [16]), and features of vasculitis. Each centre analysed their data locally before combining aggregate summaries for pooled analysis. Categorical variables were described as counts and percentages. Analyses were performed using R computing environment (version 4.3.2, R Core Team). All participants were included in the analysis regardless of missing data. Ethical approval was not required as this study comprised clinical practice audit/QIP. Participating sites gained approval from their local clinical audit/QIP services and all centres conducted this evaluation in accordance with local governance policies. Results Across the four sites, 294 cross-sectional imaging studies were performed in 261 patients. These compromised 137 (46.6%) CMR, 40 (13.6%) CTCA, and 117 (39.8%) PET scans. All PET scans were performed using 18F-FDG. Most patients were aged 40–74 years (65.9%), female (72.4%) and of White ethnicity (72.4%). The distribution of rheumatic IMIDs was as follows: 143 (54.8%) had vasculitis, 52 (19.9%) SLE, 30 (11.5%) SSc, 27 (10.3%) IIM and 9 (3.4%) SS. Among patients with vasculitis, 76 (53.1%) had LVV. 125 (47.9%) patients had a disease duration of 1–5 years. Overall, 199 (76.2%) patients were receiving a conventional synthetic DMARD, 36 (13.8%) were on a biologic DMARD and 135 (51.7%) were on concurrent corticosteroids. Dyslipidaemia (43.3%) and hypertension (39.5%) were the most common cardiovascular risk factors. Diabetes mellitus (11.5%), current smoking (6.5%), ischaemic heart disease (4.6%), family history of premature cardiovascular disease (4.6%) and cerebrovascular disease (2.7%) were less prevalent (Supplementary Table S1). Indications for cardiovascular imaging Clinical indications varied by modality and centre (Table 1). Scans may have been requested by cardiology or rheumatology teams. Overall, CMR was most commonly requested for elevated cardiac biomarkers (36.5%) and/or presence of cardiac symptoms (35.8%). It was also used as part of routine rheumatic IMID evaluation (including in the absence of symptoms) in 28 (20.4%) scans and to follow up on abnormal imaging findings (echocardiography and/or prior CMR) in 21 (15.3%) scans. In contrast, CTCA was generally performed in the presence of cardiac symptoms, accounting for 29 (72.5%) scans. The 117 PET scans were undertaken primarily in patients LVV with raised inflammatory markers (46.2%) or for wider symptoms related to the underlying IMID (46.2%), and therefore did not necessarily comprise a cardiac gated protocol. Table 1Indications for tier 2 cardiovascular imaging.IndicationCentre 1Centre 2Centre 3Centre 4TotalCMR, n7862717137 Cardiac symptoms2 (28.6)26 (30.2)9 (33.3)12 (70.6)49 (35.8) Raised inflammatory markers (CRP/ESR)0005 (29.4)5 (3.6) Raised cardiac biomarkers (troponin/proBNP)1 (14.3)21 (24.4)15 (55.6)13 (76.5)50 (36.5) IMID evaluation016 (18.6)4 (14.8)8 (47.1)28 (20.4) Abnormal echocardiogram Impaired ventricular function3 (42.9)11 (12.8)5 (18.5)4 (23.5)23 (16.8) Left ventricular hypertrophy07 (8.1)01 (5.9)8 (5.8) Regional wall motion abnormality2 (28.6)6 (7.0)02 (11.8)10 (7.3) Valvular disease2 (28.6)13 (15.1)06 (35.3)21 (15.3) Follow-up scan7 (100.0)11 (12.8)1 (3.7)2 (11.8)21 (15.3)CTCA, n328940 Cardiac symptoms1 (33.3)20 (71.4)8 (88.9)–29 (72.5) Raised troponin1 (33.3)01 (11.1)–2 (5.0) History of ischaemic heart disease01 (3.6)1 (11.1)–2 (5.0) Other1 (33.3)7 (25.0)0–8 (20.0)PET, n446310117 Symptomatic–27 (61.4)25 (39.7)2 (20.0)54 (46.2) Raised inflammatory markers (CRP/ESR)–15 (34.1)31 (49.2)8 (80.0)54 (46.2) IMID evaluation–22 (50.0)4 (6.3)10 (100.0)36 (30.8) Follow-up scan–13 (29.5)14 (22.2)1 (10.0)28 (23.9)Data are presented as n (%). Each scan may have had one or more indications. –, indicates data was not available. CMR: cardiac magnetic resonance; proBNP: pro-B-type natriuretic peptide; IMID: immune-mediated inflammatory disease; CTCA: CT coronary angiography. Indications for tier 2 cardiovascular imaging. Data are presented as n (%). Each scan may have had one or more indications. –, indicates data was not available. CMR: cardiac magnetic resonance; proBNP: pro-B-type natriuretic peptide; IMID: immune-mediated inflammatory disease; CTCA: CT coronary angiography. Cardiovascular involvement on imaging Across the three modalities, cardiovascular involvement was identified in 175/294 (59.5%) scans which represented 163 patients. This consisted of: 89 (65.0%) CMR, 63 (53.8%) PET and 23 (57.5%) CTCA. Among these, vasculitis was the most common IMID accounting for 53.7%, with LVV representing the predominant diagnosis. This was followed by SLE (22.3%), SSc (10.9%), IIM (10.3%) and SS (2.9%). Notably, a significant proportion of patients with confirmed cardiac involvement had no cardiac or non-cardiac symptoms at the time of assessment. This was the case for 61/89 (68.5%) CMR, 54/63 (85.7%) PET, and 4/23 (17.4%) CTCA scans. Among the 89 abnormal CMR studies, LGE indicative of focal myocardial fibrosis was observed in 37 (41.6%). Other notable abnormalities included chamber dilatation (36.0%), myocardial involvement (36.0%; based on elevated extracellular volume or T1 values), myocardial oedema (21.3%; based on T2 mapping), pericardial involvement (31.5%) and valvular abnormalities (25.8%). Sixty-two (69.7%) patients had preserved LVEF (Fig. 1A). (A) Cardiovascular abnormalities identified on CMR; (B) cardiovascular abnormalities identified on PET; (C) number of vessel involvement on CTCA; (D) stenosis severity based on maximum severity across all vessels on CTCA; (E) coronary artery calcium score on CTCA. CMR: cardiac magnetic resonance; CTCA: CT coronary angiography Of the 63/117 PET scans with reported abnormality, the most frequent findings were consistent with LVV. Aortic uptake was present in 57 (90.5%) scans, subclavian involvement was seen in 29 (46.0%) and carotid involvement in 12 (19.0%). Additionally, pericardial involvement was identified in 10 (15.9%) scans, and evidence of atherosclerosis was seen in 5 (7.9%) scans (Fig. 1B). Among the 23 abnormal CTCA studies, 18 (78.3%) were consistent with single- or two-vessel disease (Fig. 1C). Stenosis severity ranged from minimal (30.4%) to severe (17.4%) (Fig. 1D). Eleven (47.8%) patients had either no coronary artery calcification or only mild CAC (Fig. 1E). Radiographic features consistent with vasculitis such as aneurysm, vascular thickening or pulmonary hypertension were present in three (13.0%) CTCA scans. Impact on management Of the 163 patients with abnormal imaging, 97 (59.5%) were referred to or discussed with cardiology, with ongoing monitoring and regular follow-up (new and continuation) under the cardiology team in 56 (57.7%) patients (Supplementary Table S2). Cardiac pharmacotherapy (preventative and/or prognostic) was commenced in 35 (36.1%) patients, 21 (21.6%) underwent further cardiac investigations and 2 (2.1%) had an onward referral for surgical management. Imaging findings also prompted changes to IMID treatment in 51 (31.3%) patients. Among these, corticosteroid therapy was initiated or escalated in 28 (54.9%), DMARDs escalated in 23 (45.1%) and enhanced clinical surveillance commenced in 9 (17.6%). Only 39 (23.9%) patients were discussed in a formal rheumatology multidisciplinary team (MDT). Discussion This multicentre evaluation demonstrates a substantial burden of cardiovascular involvement in IMIDs, with marked variation in imaging indications, modality and management across centres. These findings highlight the heterogeneity of cardiovascular involvement in IMIDs, disease subtypes, and the evolving role of advanced cardiovascular imaging in routine clinical care, providing a valuable platform for informing current clinical practice and future longitudinal studies. PET was most frequently utilized for LVV, where its role in disease monitoring is well established. CMR is increasingly used to detect direct IMID-related inflammatory myopericardial syndrome [17], and accounted for almost half of the scans. CTCA was likely under-represented as standard coronary artery disease pathways typically operate outside rheumatology services. Nevertheless, elevated CAC scores on CTCA have been reported across rheumatic IMIDs such as in SLE, where patients were up to 10 times more likely to have calcification than controls [18], and therefore it remains an optimal tool for screening for ASCVD. Valvular abnormalities were reported in approximately one-quarter of patients, although their clinical significance is uncertain. The aetiology is likely heterogeneous, reflecting both potential IMID-related involvement and common causes such as primary degenerative disease or secondary changes from other cardiac conditions. Variation in imaging practice across centres likely reflects differences in the underlying rheumatic IMID, the type of cardiovascular involvement being considered, and local access to each modality. Triggers for advanced imaging and subsequent management also differed. For example, CMR was requested for a broad range of indications, including elevated troponin and/or N-terminal proBNP levels, cardiac symptoms and persistently raised inflammatory markers. PET was used predominantly in patients with vasculitis. A notable proportion of the patients with cardiovascular involvement were asymptomatic at the time of assessment. While this is expected in LVV, where markers of systemic inflammation often guide disease monitoring, it was also observed in patients undergoing CMR. CMR can detect myocardial inflammation (parametric mapping) and injury (parametric mapping and LGE) and are reported in up to 40–60% of asymptomatic IMID cohorts [19–21]. Our real-world study reported use of CMR in patients without cardiac symptoms and abnormal mapping in a subset of these, including in the absence of LGE. The assumption with subclinical CMR findings is that they may precede adverse cardiac outcomes although large, longitudinal studies are lacking to confirm the mechanisms. Caution is also required when interpreting these values in asymptomatic patients especially in conditions characterized by general systemic inflammatory environment and co-existent renal, and or pulmonary vascular disease which may cause non-specific myocardial tissue oedema. Nevertheless, the poor prognosis of clinically overt presentations underscores the opportunity of identifying disease earlier. In current clinical practice, such abnormalities may prompt closer surveillance and repeat imaging. Whether these changes are modifiable with escalation of immunosuppressive therapy and limits progression is unclear, but treatment may be prompted by wider evidence of disease activity. Despite the strengths of advanced cardiovascular imaging, important limitations must be acknowledged. Interpretation of CMR is influenced by variability across scanners and protocols, and as indicated above, lacks absolute disease specificity. In some instances, histology may still be required. 18F-FDG-PET is additionally limited by high physiological myocardial glucose uptake which may result in false positives and the lack of a cardiac gated protocol precludes comprehensive assessment of myocardial involvement. IMIDs have distinct clinical and pathophysiological mechanisms, and thus a uniform approach to cardiovascular risk assessment is unlikely to capture this heterogeneity. For example, a proportion of individuals with SSc primary cardiac involvement may be characterized by marked microvascular pathology and more extensive myocardial fibrosis [22] than the myocardial inflammation otherwise seen in cases of SSc, IIM or SLE, but more extensive studies are needed. These disease-specific differences should be considered when selecting imaging modality and interpreting findings. Taken together, these findings support a pragmatic multimodal diagnostic approach to cardiovascular involvement in IMIDs. Clinical assessment should integrate symptoms, examination, cardiac biomarkers, IMID-specific measures of disease activity and targeted imaging. CMR may be preferentially used to assess myocardial involvement, PET to evaluate inflammatory vascular activity and CTCA to assess coronary artery plaque when clinically indicated. Importantly, fewer than a quarter of patients with cardiovascular involvement were discussed in formal MDTs, and only one participating centre had access to a dedicated cardio-rheumatology MDT. This highlights an important gap in current pathways. Given the complexity of managing these patients, there is an urgent need to establish joint cardio-rheumatology MDTs, analogous to the established MDTs with respiratory and renal teams. Such collaboration would ensure education and integrated decision-making, and improve patient outcomes. The nature of this study naturally introduces several limitations. The inability to share raw data restricted our analysis to prevalence estimates; as such, we were unable to explore associations between clinical characteristics, disease phenotypes, imaging findings or the impact of treatments. The absence of longitudinal follow-up precluded any assessment of long-term outcomes. Finally, as data were extracted retrospectively from routine clinical records, their completeness and accuracy depended on local documentation and may have led to inconsistencies or missing information. Nevertheless, this evaluation provides a valuable descriptive overview of current practice and variation across UK centres. It supports the need for multimodal imaging approaches to capture the diverse cardiovascular phenotypes. It also highlights the need for improved cross-specialty collaboration through formal MDTs for learning and to improve patient outcomes. Supplementary Material Acknowledgements M.H.B. is a National Institute for Health and Care Research (NIHR) Senior Investigator and is supported by the NIHR Manchester Biomedical Research Centre (NIHR203308). S.P. is supported by the British Heart Foundation CH/16/2/32089 and the NIHR Leeds Biomedical Research Centre (NIHR203331). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The graphical abstract was created using Figurelabs.ai. Contributor Information Leher Gumber, Centre for Musculoskeletal Research, Division of Musculoskeletal & Dermatological Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. Mohammed Askari Meghji, Manchester University NHS Foundation Trust, Manchester, UK. Vishal Kakkar, Leeds Biomedical Research Centre, National Institute for Health Research, Leeds Teaching Hospital NHS Trust, Leeds, UK. Karthikeyan Sivasankaran, Department of Medicine, Northumbria Healthcare NHS Foundation Trust, Newcastle upon Tyne, UK. Zahra M Iftikhar, Department of Rheumatology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. Najla Elndari, Department of Rheumatology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. Charlotte Talbot, Institute of Inflammation and Aging, University of Birmingham, Birmingham, UK; Department of Rheumatology, Sandwell and West Birmingham NHS Trust, Birmingham, UK. Jason M Tarkin, Section of Cardiorespiratory Medicine, Victor Phillip Dahdaleh Heart & Lung Research Institute, University of Cambridge, Cambridge, UK. Sven Plein, Biomedical Imaging Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK; School of Biomedical Engineering and Imaging Sciences, Kings College London, London, UK. Marc R Dweck, Centre for Cardiovascular Science, Chancellors Building, Little France Crescent, University of Edinburgh, Edinburgh, UK. Taryn Youngstein, National Heart & Lung Institute, Imperial College London, London, UK; Department of Rheumatology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK. Ziad Mallat, Section of Cardiorespiratory Medicine, Victor Phillip Dahdaleh Heart & Lung Research Institute, University of Cambridge, Cambridge, UK. Lesley-Anne Bissell, Leeds Biomedical Research Centre, National Institute for Health Research, Leeds Teaching Hospital NHS Trust, Leeds, UK. Jonathan Heaney, Department of Rheumatology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. John Reynolds, Institute of Inflammation and Aging, University of Birmingham, Birmingham, UK; Department of Rheumatology, Sandwell and West Birmingham NHS Trust, Birmingham, UK. Maya H Buch, Centre for Musculoskeletal Research, Division of Musculoskeletal & Dermatological Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. Supplementary material Supplementary material is available at Rheumatology online. Data availability The data that support the findings of this study are available within the article and its supplementary material. Funding No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript. Disclosure statement: The authors have declared no conflicts of interest. References Associated Data Supplementary Materials Data Availability Statement The data that support the findings of this study are available within the article and its supplementary material.